Nature of Business and Basis of Presentation - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands					3 Months Ended
	Mar. 10, 2022	Apr. 06, 2021	Nov. 09, 2020	Mar. 12, 2020	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Proceeds from Sale of Equity Method Investments	$ 130,000
Net proceed from issuance of common stock						$ 1,454
Net income					92,105	$ (1,073)
Accumulated deficit					332,027		$ 424,132
Oxford Biomedica Plc Member
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Upfront Payment Received					130,000
Proceeds from Sale of Equity Method Investments					$ 50,000
Maximum
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Proceeds through future financings				$ 148,400
Common Stock
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Issuance of common stock, net of discounts and issuance costs, Share						114,914
Follow-on Offering [Member] | Common Stock
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Issuance of common stock, net of discounts and issuance costs, Share		6,596,306
Shares issued price per share		$ 7.58
Net proceeds after deducting underwriting discounts and commissions and offering expenses		$ 49,700
Common stock offering expenses		$ 300
Underwriters Option | Common Stock
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Issuance of common stock, net of discounts and issuance costs, Share		989,445
Shares issued price per share		$ 7.58
Private Placement
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Issuance of common stock, net of discounts and issuance costs, Share			5,000,000
Shares issued price per share			$ 12.00
Net proceed from issuance of common stock			$ 60,000
ATM
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Issuance of common stock, net of discounts and issuance costs, Share					0
Proceeds through future financings					$ 148,400
ATM | Oxford Biomedica Plc Member
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Sale of Stock, Percentage of Ownership after Transaction					80.00%
ATM | Homology Member
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Sale of Stock, Percentage of Ownership after Transaction					20.00%
ATM | Maximum
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Proceeds through future financings				$ 150,000